메뉴 건너뛰기
Thrombosis and Haemostasis
Volumn 104, Issue 5, 2010, Pages 1078-1079
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma
Author keywords

[No Author keywords available]
Indexed keywords

ANTITHROMBIN; CHROMOGENIC SUBSTRATE; FONDAPARINUX; HEPARIN; PLASMA PROTEIN; PROTHROMBIN; RIVAROXABAN; THROMBIN;
EID: 78149492327     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-03-0204     Document Type: Letter
Times cited : (109)
References (9)
  • 1
    • 45949083155 scopus 로고    scopus 로고
    • New antithrombotic drugs: American College of Chest Physicians Evidence-based clinical practice guidelines
    • th edition Erratum in Chest 2008; 134: 473
    • th edition) Chest 2008; 133 (Suppl 8): 234S-256S. Erratum in Chest 2008; 134: 473.
    • (2008) Chest , vol.133 , Issue.SUPPL. 8
    • Weitz, J.I.1    Hirsh, J.2    Samama, M.M.3
  • 2
    • 38349147756 scopus 로고    scopus 로고
    • New oral anticoagulants in atrial fibrillation
    • Turpie AGG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2007; 29:155-165.
    • (2007) Eur Heart J , vol.29 , pp. 155-165
    • Turpie, A.G.G.1
  • 3
    • 70449574622 scopus 로고    scopus 로고
    • Direct inhibitors of coagulation proteins - The end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    • Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy ? Thromb Haemost 2009; 102: 892-899.
    • (2009) Thromb Haemost , vol.102 , pp. 892-899
    • Laux, V.1    Perzborn, E.2    Heitmeier, S.3
  • 4
    • 4644316829 scopus 로고    scopus 로고
    • Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra®) anti-Xa activity
    • Depasse F, Gerotziafas GT, Busson J, et al. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra®) anti-Xa activity. J Thromb Haemost 2004; 2: 346-348.
    • (2004) J Thromb Haemost , vol.2 , pp. 346-348
    • Depasse, F.1    Gerotziafas, G.T.2    Busson, J.3
  • 5
    • 0026707775 scopus 로고
    • Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring efficacy, and safety
    • Hirsh J, Dalen JE, Deykin D, et al. Heparin : mechanism of action, pharmacokinetics, dosing considerations, monitoring efficacy, and safety. Chest 1992; 102: 337S-351S.
    • (1992) Chest , vol.102
    • Hirsh, J.1    Dalen, J.E.2    Deykin, D.3
  • 6
    • 78149489472 scopus 로고    scopus 로고
    • Quantitation of Rivaroxaban: Validation of a commercial chromogenic antiXa test (Hyphen Biomed) in an inter-laboratory setting
    • RivaMoS study group Abstract SY12-04
    • Asmis LM, Alberio LA, Angelillo-Scherrer A, et al. Quantitation of Rivaroxaban: validation of a commercial chromogenic antiXa test (Hyphen Biomed) in an inter-laboratory setting (RivaMoS study group). Haemostaseologie 2010; 30: Abstract SY12-04.
    • (2010) Haemostaseologie , vol.30
    • Asmis, L.M.1    Alberio, L.A.2    Angelillo-Scherrer, A.3
  • 7
    • 77952044405 scopus 로고    scopus 로고
    • Assessment of laboratory assays to measure rivaroxaban - An oral, direct factor Xa inhibitor
    • Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
    • (2010) Thromb Haemost , vol.103 , pp. 815-825
    • Samama, M.M.1    Martinoli, J.L.2    LeFlem, L.3
  • 8
    • 25844525489 scopus 로고    scopus 로고
    • Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct FXa inhibitor
    • Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct FXa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 412-421
    • Kubitza, D.1    Becka, M.2    Voith, B.3
  • 9
    • 51349095537 scopus 로고    scopus 로고
    • Population pharmacokinetics and pharmacodynamics of once- and twice-daily Rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
    • Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily Rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
    • (2008) Thromb Haemost , vol.100 , pp. 453-461
    • Mueck, W.1    Borris, L.C.2    Dahl, O.E.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.